V
Véronique Saada
Researcher at Institut Gustave Roussy
Publications - 66
Citations - 3740
Véronique Saada is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Myeloid & Leukemia. The author has an hindex of 19, co-authored 55 publications receiving 2850 citations. Previous affiliations of Véronique Saada include French Institute of Health and Medical Research & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang,Jeremy Travins,Byron DeLaBarre,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Stefanie Schalm,Erica Hansen,Kimberly Straley,Andrew Kernytsky,Wei Liu,Camelia Gliser,Hua Yang,Stefan Gross,Erin Artin,Véronique Saada,Elena Mylonas,Elena Mylonas,Elena Mylonas,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Janeta Popovici-Muller,Jeffrey O. Saunders,Francesco G. Salituro,Shunqi Yan,Stuart Murray,Wentao Wei,Yi Gao,Lenny Dang,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen +38 more
TL;DR: Evidence is provided that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer, and a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDh2/ R140Q is developed.
Journal ArticleDOI
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.
Aymeric Silvin,Nicolas Chapuis,Garett Dunsmore,Anne-Gaëlle Goubet,Agathe Dubuisson,Lisa Derosa,Carole Almire,Clémence Hénon,Olivier Kosmider,Nathalie Droin,Philippe Rameau,Cyril Catelain,Alexia Alfaro,Charles Dussiau,Chloé Friedrich,Elise Sourdeau,Nathalie Marin,T.-A. Szwebel,Delphine Cantin,Luc Mouthon,Didier Borderie,Marc Deloger,Delphine Bredel,Severine Mouraud,Damien Drubay,Muriel Andrieu,Anne-Sophie Lhonneur,Véronique Saada,Annabelle Stoclin,Christophe Willekens,Fanny Pommeret,Frank Griscelli,Lai Guan Ng,Zheng Zhang,Pierre Bost,Pierre Bost,Ido Amit,Fabrice Barlesi,Aurélien Marabelle,Frédéric Pène,Bertrand Gachot,Fabrice Andre,Fabrice Andre,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Florent Ginhoux,Florent Ginhoux,Florent Ginhoux,Michaela Fontenay,Eric Solary,Eric Solary +51 more
TL;DR: It is shown that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe COVID-19 form, suggesting a predictive value that deserves prospective evaluation.
Journal ArticleDOI
Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays
Antoine-Emmanuel Saliba,Laure Saias,Eleni Psychari,Nicolas Minc,Damien Simon,François-Clément Bidard,Claire Mathiot,Jean-Yves Pierga,Vincent Fraisier,Jean Salamero,Véronique Saada,Françoise Farace,Philippe Vielh,Laurent Malaquin,Jean-Louis Viovy +14 more
TL;DR: Ephesia provides a powerful approach to cell capture and typing allowing fully automated high resolution and quantitative immunophenotyping and morphological analysis, and requires at least 10 times smaller sample volume and cell numbers than cytometry, potentially increasing the range of indications and the success rate of microbiopsy-based diagnosis and reducing analysis time and cost.
Journal ArticleDOI
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine E. Yen,Jeremy Travins,Fang Wang,Muriel D. David,Muriel D. David,Erin Artin,Kimberly Straley,Anil K. Padyana,Stefan Gross,Byron DeLaBarre,Erica Tobin,Yue Chen,Raj Nagaraja,Sung Choe,Lei Jin,Zenon D. Konteatis,Giovanni Cianchetta,Jeffrey O. Saunders,Francesco G. Salituro,Cyril Quivoron,Cyril Quivoron,Paule Opolon,Olivia Bawa,Véronique Saada,Véronique Saada,Angelo Paci,Sophie Broutin,Olivier Bernard,Olivier Bernard,Stéphane de Botton,Stéphane de Botton,Benoit S. Marteyn,Benoit S. Marteyn,Monika Pilichowska,Yingxia Xu,Cheng Fang,Fan Jiang,Wentao Wei,Shengfang Jin,Lee Silverman,Wei Liu,Hua Yang,Lenny Dang,Marion Dorsch,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Scott A. Biller,Shin-San Michael Su +47 more
TL;DR: It is shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development.
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.